Arcturus Therapeutics Holdings Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ARCT in the last 30 days.
See all $ARCT insider activity →A Phase 1 trial of Arcturus Therapeutics' self-amplifying mRNA H5N1 flu vaccine, ARCT-2304, showed strong immune responses and durability when doses were spaced eight weeks apart. The vaccine, encoding both HA and NA antigens, was well-tolerated across dose levels. The study, funded by U.S. HHS, suggests potential for pandemic preparedness.
FEDERATED HERMES, INC. reduced its stake in Arcturus Therapeutics (ARCT) by 49.21% on Sept. 30, 2026, selling 1.63 million shares at $13.69 each. The firm now holds 1.68 million shares, 5.90% of ARCT's outstanding shares. Arcturus, a clinical-stage mRNA company, has a market cap of $341.93 million and faces valuation concerns, with a GF Value estimate of $2.12, indicating significant overvaluation.
Analysts updated price targets for several companies. Needham raised CrowdStrike's (CRWD) target to $310, Baird increased Humana's (HUM) to $596, and others adjusted targets for Robinhood (HOOD), Webull (BULL), Align (ALGN), Pacira (PCRX), Sailpoint (SAIL), Unity (U), and Arcturus (ARCT). AT&T's (T) target was cut by Scotiabank.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ARCT (Arcturus Therapeutics Holdings Inc.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent ARCT coverage spans financial news, market movers and technology.
Positive Phase 1 data may lift ARCT stock as investors view platform as promising for pandemic flu vaccines
The large sell may push ARCT lower as the market absorbs the fund's reduced exposure.
Positive outlook for Arcturus.
Positive sentiment driven by outbreak‑related speculation.
Positive trial data supports continued development and potential future value.
AlphAI scores every news story that mentions ARCT with an AI model for sentiment and relevance, and aggregates insider trades from Arcturus Therapeutics Holdings Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
A Phase 1 trial of Arcturus Therapeutics' self-amplifying mRNA H5N1 flu vaccine, ARCT-2304, showed strong immune responses and durability when doses were spaced eight weeks apart. The vaccine, encoding both HA and NA antigens, was well-tolerated across dose levels. The study, funded by U.S. HHS, suggests potential for pandemic preparedness.
3 min readFEDERATED HERMES, INC. reduced its stake in Arcturus Therapeutics (ARCT) by 49.21% on Sept. 30, 2026, selling 1.63 million shares at $13.69 each. The firm now holds 1.68 million shares, 5.90% of ARCT's outstanding shares. Arcturus, a clinical-stage mRNA company, has a market cap of $341.93 million and faces valuation concerns, with a GF Value estimate of $2.12, indicating significant overvaluation.
2 min readAnalysts updated price targets for several companies. Needham raised CrowdStrike's (CRWD) target to $310, Baird increased Humana's (HUM) to $596, and others adjusted targets for Robinhood (HOOD), Webull (BULL), Align (ALGN), Pacira (PCRX), Sailpoint (SAIL), Unity (U), and Arcturus (ARCT). AT&T's (T) target was cut by Scotiabank.
2 min readNovavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.
2 min readBiotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
3 min readAnalysts made several rating changes and price target adjustments. JPMorgan upgraded CoreWeave, Welltower, and Macerich, while Citi downgraded Dropbox. Bernstein upgraded Quanta Services, and Morgan Stanley initiated Imax and Nvidia with overweight ratings. Other notable moves include upgrades for Arcturus Therapeutics, Dollar General, and The Brink's Company, and initiations for NeOnc Technologies, Energy Services of America, BayCom, Avidbank, and SpaceX.
3 min readCitigroup upgraded Arcturus Therapeutics to Buy from Neutral and raised its price target to $20 from $8. The stock has seen a 5-day change of $13.30, a 1st Jan change of -7.51%, and a 1-year change of +116.97%. The upgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.
1 min readArcturus Therapeutics (ARCT) shares rose 5.3% after reporting positive Phase 2 data for ARCT-810 and introducing LUNAR 2.0, a next-gen mRNA platform. The company plans to integrate ARCT-2601 into its Phase 2 study by 2026 and will acquire myNEO to enhance AI-driven mRNA design.
4 min readArcturus Therapeutics (ARCT) will present Phase 2 clinical data for ARCT-810, a treatment for Ornithine Transcarbamylase (OTC) deficiency, on September 23, 2026. The company's mRNA liver therapeutics platform will also be discussed. ARCT-810 has received Orphan Drug and Fast Track designations from the FDA. OTC deficiency affects approximately 10,000 people in Europe and the U.S.
2 min readArcturus Therapeutics (ARCT), MediciNova (MNOV), Inovio (INO), and Eyepoint Pharmaceuticals (EYPT) have upcoming binary events. ARCT has Phase II OTC-deficiency data and a Q4 cystic-fibrosis decision. MNOV expects Phase II data in September and COMBAT-ALS readout by year-end. INO awaits an FDA decision on INO-3107 in October. EYPT anticipates LUCIA Phase III data in Q4. All face significant binary risk.
2 min read
